Literature DB >> 17551252

Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees.

Aglaya G Iyevleva1, Konstantin G Buslov, Alexandr V Togo, Dmitry E Matsko, Vasily P Filimonenko, Vladimir M Moiseyenko, Evgeny N Imyanitov.   

Abstract

BACKGROUND: Measurement of intratumoral expression of dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) may have some value in predicting the response to fluoropyrimidine-containing therapy. PATIENTS AND METHODS: We attempted to validate this association in a series of Russian metastatic colorectal cancer cases. While replicating already published protocols, we unexpectedly found that the use of commonly utilized gene referees, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin, may lead to artifacts due to pseudogene-driven amplification from the genomic DNA template. We have developed a real-time PCR protocol which amplifies short PCR fragments, thus allowing efficient analysis of archival formalin-fixed paraffin-embedded tumor samples, and relies on succinate dehydrogenase (SDHA) as a gene referee, therefore avoiding amplification from genomic DNA.
RESULTS: Low content of DPD transcripts was observed in 13/20 (65%) patients with disease control (tumor response or disease stabilization) as compared to only 3/9 (33%) subjects with progressive disease (p = 0.11). Despite the low number of patients, this association reached the level of statistical significance when similar analysis was done for TS expression (11/20 (55%) vs. 1/9 (11%); p = 0.03).
CONCLUSIONS: Our data confirm that low DPD and TS expressors have higher chances of success of fluoropyrimidine-containing regimens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551252     DOI: 10.1159/000102046

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  6 in total

1.  Expression of transient receptor potential vanilloid channels TRPV5 and TRPV6 in human blood lymphocytes and Jurkat leukemia T cells.

Authors:  Irina O Vassilieva; Victor N Tomilin; Irina I Marakhova; Alla N Shatrova; Yuri A Negulyaev; Svetlana B Semenova
Journal:  J Membr Biol       Date:  2012-11-01       Impact factor: 1.843

2.  Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence.

Authors:  Evgeny N Suspitsin; Aniruddh Kashyap; Kseniya V Shelekhova; Anna P Sokolenko; Ekatherina Sh Kuligina; Aglaya G Iyevleva; Alexandr V Kornilov; Volker Ehemann; Grigoriy A Yanus; Svetlana N Aleksakhina; Elena V Preobrazhenskaya; Olga A Zaitseva; Olga S Yatsuk; Valeriy F Klimashevsky; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-06-26       Impact factor: 3.064

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.

Authors:  Vladimir M Moiseyenko; Nikita M Volkov; Evgeny N Suspistin; Grigoriy A Yanus; Aglaya G Iyevleva; Ekatherina Sh Kuligina; Alexandr V Togo; Alexandr V Kornilov; Alexandr O Ivantsov; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

5.  Identification of Hub Genes Associated With Sensitivity of 5-Fluorouracil Based Chemotherapy for Colorectal Cancer by Integrated Bioinformatics Analysis.

Authors:  Ya Wang; Qunhui Wei; Yuqiao Chen; Shichao Long; Yuanbing Yao; Kai Fu
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

6.  Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.

Authors:  Xingxing Huang; Kun Ke; Weiwei Jin; Qianru Zhu; Qicong Zhu; Ruyi Mei; Ruonan Zhang; Shuxian Yu; Lan Shou; Xueni Sun; Jiao Feng; Ting Duan; Yiping Mou; Tian Xie; Qibiao Wu; Xinbing Sui
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.